Complementary combined captopril and terbutaline therapy in severe chronic congestive heart failure

Najam A. Awan, Kathleen E. Needham, Henry Lui, Jack Rutledge, Ezra A Amsterdam, Dean T. Mason

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The hemodynamic effects of captopril (CPT) alone and in combination with the beta-adrenergic receptor agonist terbutaline (TBT) were evaluated in 10 patients with severe chronic congestive heart failure (CHF). The heart rate remained unchanged, while CPT lowered mean systemic blood pressure from 86 to 64 mm Hg (p < 0.001) and decreased left ventricular filling pressure markedly from 27 to 19 mm Hg (p < 0.001). The addition of TBT produced no further change in these variables (p > 0.05). Simultaneously, CPT augmented cardiac index (Cl) from 2.1 to 2.9 L/min/m2 (p < 0.01) and stroke index (Sl) from 27 to 37 ml/beat/m2 (p < 0.001). Concomitant CPT-TBT further raised Cl to 3.2 L/min/m2 and Sl to 40 ml/beat/m2 (both p < 0.001). Further, the CPT-effected decline in total systemic vascular resistance from 1577 to 841 dynes · sec · cm-5 (p < 0.001) was not reduced additionally by CPT-TBT combination (p > 0.05). These results indicate that both CPT and TBT markedly augment cardiac function in CHF. Moreover, the salutary effects of the systemic vasodilator appear additive to the beneficial actions of the beta-adrenergic receptor agonist, thereby providing substantial augmentation of the function of the failing heart.

Original languageEnglish (US)
Pages (from-to)1224-1228
Number of pages5
JournalAmerican Heart Journal
Issue number5 PART 2
StatePublished - 1982

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Complementary combined captopril and terbutaline therapy in severe chronic congestive heart failure'. Together they form a unique fingerprint.

Cite this